Highest-materiality recent filing
OnKure Q1 loss $15.2M; cash $192M; nominates two new PI3Kα inhibitors; halting OKI-219
Net loss of $15.2M ($1.11 per share) for Q1 2026 vs $15.9M ($1.19 per share) in Q1 2025.
OnKure raises $150M in PIPE; plans IND filings for PI3Kα pan-mutant inhibitors in H1 2027
Private placement of ~26.7M shares at $4.15 and ~9.4M pre-funded warrants; gross proceeds ~$150M.
OnKure Therapeutics Q4 2025 net loss narrows to $13.5M; expects March data readouts
Net loss of $13.5M ($0.99/sh) for Q4 2025 vs $17.4M ($1.37/sh) in Q4 2024; expenses decreased.
OnKure Q3 net loss $14.7M; cash $70.3M; initial data from PI3K trial pushed to Q1 2026
Cash $70.3M as of Sept 30, 2025; expected to fund operations into Q4 2026.
OnKure enters ATM offering agreement with Leerink Partners; up to 3% fee
Sales agreement with Leerink Partners for at-the-market offering of Class A common stock.
OnKure reports Q2 net loss $15.4M; OKI-219 trial data expected Q4 2025
Cash $83.4M as of June 30, 2025; runway expected into Q4 2026.
OnKure Therapeutics posts updated corporate presentation to IR website
OnKure posted an updated corporate presentation on June 26, 2025.
Dr. Isaac Manke elected with 4,589,481 for, 882,303 withheld; Dr. Nicholas Saccomano with 5,209,380 for, 262,404 withheld.
OnKure Q1 net loss $15.9M, cash $96.7M; PIKture-01 trial on track for H2 2025 data
Net loss of $15.9M ($1.19 per share) vs $9.5M in Q1 2024; R&D expense rose to $13.0M.
OnKure Q4 2024 net loss $17.4M; cash $110.8M; PIKture-01 data in H2 2025
Net loss Q4 2024 $17.4M ($1.37/share) vs $9.5M ($30.14/share) in Q4 2023; R&D expense rose $5.6M.
OKI-219 well-tolerated in first human trial; no hyperglycemia, Part 1b combo initiated
17 patients dosed across 300–900 mg BID; no dose interruptions, reductions, or discontinuations.
Legacy OnKure posts $35.2M net loss in 9mo; auditor switched to KPMG post-merger
Net loss of $35.2M for nine months ended Sep 30, 2024, vs $25.9M in prior year.
OnKure completes reverse merger with Reneo; trades as OKUR with $65M PIPE
Reneo acquired OnKure in reverse merger; each OnKure common share exchanged for 0.023596 Class A shares.
Reneo stockholders approve all proposals for OnKure merger at special meeting
Proposal 1 (stock issuance for merger) approved: 21.87M for, 110.6K against.
Reneo faces two shareholder lawsuits over OnKure merger proxy; provides supplemental disclosures
Two complaints filed in NY Supreme Court allege misrepresentations/omissions in proxy regarding financial projections and advisor conflicts.
Reneo Pharma terminates CDO Ashley Hall amid planned merger with OnKure
Ashley F. Hall, Chief Development Officer, terminated effective Sept 13, 2024.
Reneo Pharma Q2 net loss $5.4M; merger with OnKure on track for H2 2024
Net loss of $5.4M ($0.16 per share) vs $19.5M ($0.65) in Q2 2023; cash $76.7M at June 30.
OnKure stockholders expected to own ~69.4% of combined entity; Reneo holders ~30.6% on fully-diluted basis.
Reneo Pharmaceuticals initiates strategic alternatives review after failed trial; Q1 net loss $8.4M
STRIDE study of mavodelpar in primary mitochondrial myopathies missed all endpoints in Dec 2023.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Also on October 4, 2024, Andrew Phillips, Ph.D. was appointed as the Chair of the Board.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
the Company terminated the employment of Ashley F. Hall, J.D., the Company’s Chief Development Officer, effective as of September 13, 2024.
each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.
each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.
each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.
Max materiality 1.00 · Median 0.65 · Most common event other_material